The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 12, 2008
Filed:
Sep. 01, 2004
Paul Joseph Cox, Flemington, NJ (US);
Shelley Bower, Bedminster, NJ (US);
David John Aldous, Gillette, NJ (US);
Peter Charles Astles, Kent, GB;
Daniel Gerard Mcgarry, Branchburg, NJ (US);
Christopher Hulme, Phoenixville, PA (US);
John Robinson Regan, Larchmont, NY (US);
Fu-chih Huang, Belle Mead, NJ (US);
Stevan Wakefield Djuric, Libertyville, PA (US);
Kevin Joseph Moriarty, Norristown, PA (US);
Rose Mappilakunnel Mathew, Collegeville, PA (US);
Gregory Bernard Poli, Bethlehem, PA (US);
Paul Joseph Cox, Flemington, NJ (US);
Shelley Bower, Bedminster, NJ (US);
David John Aldous, Gillette, NJ (US);
Peter Charles Astles, Kent, GB;
Daniel Gerard McGarry, Branchburg, NJ (US);
Christopher Hulme, Phoenixville, PA (US);
John Robinson Regan, Larchmont, NY (US);
Fu-Chih Huang, Belle Mead, NJ (US);
Stevan Wakefield Djuric, Libertyville, PA (US);
Kevin Joseph Moriarty, Norristown, PA (US);
Rose Mappilakunnel Mathew, Collegeville, PA (US);
Gregory Bernard Poli, Bethlehem, PA (US);
Aventis Pharma Limited, West Malling, GB;
Abstract
This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and pharmaceutically acceptable salts of the compounds of formula (I) and N-oxides thereof, Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmnaceutical compositions comprising compoundS of formula (I), their phatmaceUtical use and methods for their preparation.